Strategy to enhance efficacy of doxorubicin in solid tumor cells by methyl-β-cyclodextrin: Involvement of p53 and Fas receptor ligand complex

Doxorubicin (DOX) is one of the preferred drugs for treating breast and liver cancers. However, its clinical application is limited due to severe side effects and the accompanying drug resistance. In this context, we investigated the effect on therapeutic efficacy of DOX by cholesterol depleting age...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohammad, Naoshad, Vikram Singh, Shivendra, Malvi, Parmanand, Chaube, Balkrishna, Athavale, Dipti, Vanuopadath, Muralidharan, Nair, Sudarslal Sadasivan, Nair, Bipin, Bhat, Manoj Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4493576/
https://www.ncbi.nlm.nih.gov/pubmed/26149967
http://dx.doi.org/10.1038/srep11853

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4493576/
https://www.ncbi.nlm.nih.gov/pubmed/26149967
http://dx.doi.org/10.1038/srep11853

Ejemplares similares